ALPROLIX® is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia B (congenital factor IX deficiency) for:
- Control and prevention of bleeding episodes
- Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- Perioperative management (surgical prophylaxis)
ALPROLIX is manufactured using a human cell line in an environment free of animal and human additives.
ALPROLIX is approved for use for the treatment of Haemophilia B in Australia and New Zealand. It is also approved in the United States, Japan, Canada, and other countries.